No items found.
Do you want to be a part of an interdisciplinary dynamic team who shares the vision of better cancer diagnostics by developing and improving RNA-based technologies?
Today, there is a need for more precise and personalized RNA-based cancer diagnostics. RNA visualization and sequencing are an integrated part of R&D programs in the pharmaceutical industry, cancer centers, institutes and hospitals. Future healthcare will increasingly depend on accurate diagnosis and subsequent personalized treatment the best possible treatment regimens for patients.
Our biotech company, MultiplexDX, aims to significantly increase the number of cancer survivors through personalized diagnostics that lead to tailored, effective and life-saving treatment. We want to bring to market a reliable, accurate, quantitative, cost-effective and multiplexed diagnostic test for cancer, which can precisely identify and quantify cancer markers in human tissues and blood.
We are now looking for an experienced Senior Nucleic Acid Chemist to take the lead in the production and R&D of modified oligonucleotides that will be used in our RNA-based diagnostic technologies and applications. In this multifaceted role, you will help to advance our next pipeline of designed diagnostic products, solve technical obstacles and track costs associated with the modified oligonucleotide synthesis, will study patents, read scientific papers, test different concepts in the laboratory and generate new ideas in collaboration with our team of innovative Molecular Biologists.
You will report to the Chief Operating Officer and be based at the headquarters in Bratislava, Slovakia.
We offer a great job with development opportunities in a highly motivating and professional environment. You may be looking for a new career path or you may simply be looking to make a difference in a small hard-working organization with the ambition to make a difference.
You will be offered the opportunity to spearhead the next ground-breaking diagnostic technologies involving modified oligonucleotide synthesis but also add value to the already exciting market.
The job will be challenging and rewarding at the same time. You will have world class colleagues, flexible working hours, 5 weeks of holiday and a negotiable salary commensurate to your qualifications (starting from €2000/month).
Application deadline is August 31st, 2019. Please send the application including your resume, cover letter and references to email@example.com.
Your application will be treated in accordance with our policies for processing of personal data incorporating the General Data Protection Regulation of the EU.
Modified oligonucleotide synthesis and preparation of RNA/DNA FISH probes, pre-adenylated sequencing adapters, qPCR probes, etc. enables more specific, precise, automated, high-throughput, multiplexed and quantitative RNA visualization and sequencing technologies that are essential for accurate and personalized cancer diagnostic applications. MultiplexDX diagnostic products combine RNA visualization and sequencing to come up with a specific “barcode” of each cancer, which suggests the specific, personalized treatment and medicines to be used, but also how long a therapy should last. In MultiplexDX diagnostic tests, multiplexing stands for cross-testing and verifying the same result from two independent perspectives, visualization and sequencing. This multiplexed platform provides the most precise clinical parameters and patient’s cancer profile, which enables an oncologist to make an evidence-based decision and target treatment quickly, directly and more accurately.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.